Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome

Anna Laura Cremonini1,2, Andrea Pasta1, Federico Carbone1,2, Luca Visconti1, Matteo Casula1, Edoardo Elia1, Aldo Bonaventura1,3, Luca Liberale1,2, Maria Bertolotto1, Nathan Artom4, Silvia Minetti1, Paola Contini1,2, Daniela Verzola1, Roberto Pontremoli1,2, Francesca Viazzi1,2, Giorgio Luciano Viviani1, Stefano Bertolini1, Aldo Pende1,2, Fabrizio Montecucco1,2 and Livia Pisciotta1,2*

1Department of Internal Medicine, University of Genoa, Genoa, Italy, 2IRCCS Ospedale Policlinico San Martino, Genoa, Italy, 3Internal Medicine Department Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy, 4Department of Internal Medicine, Ospedale S. Paolo di Savona, Savona, Italy

Background and Aim: High lipoprotein(a) [Lp(a)] is a well-established cardiovascular (CV) risk factor, but the effect of mildly elevated Lp(a) on CV health is largely unknown. Our aim was to evaluate if Lp(a) is associated with the severity of carotid atherosclerosis (CA) in the specific subset of metabolic syndrome (MetS).

Patients and Methods: Subjects with diagnosed MetS and ultrasound-assessed CA were enrolled. Those patients were categorized according to the severity of CA (moderate vs. severe), and the circulating levels of Lp(a) alongside with clinical, anthropometric, and biochemical data were collected.

Results: Sixty-five patients were finally included: twenty-five with moderate and forty with severe CA (all with asymptomatic disease). Intergroup comparison showed Lp(a) as the only significantly different variable [6 (2–12) mg/dl vs. 11.5 (6–29.5) mg/dl; p = 0.018]. Circulating levels of Lp(a) were also confirmed as the only variable independently associated with severity of CA at logistic regression analysis [OR 2.9 (95% CI 1.1–7.8); p = 0.040]. ROC curve analysis for Lp(a) confirmed a serum level of 10 mg/dl as the best cut-off value [AUC 0.675 (95% CI 0.548–0.786)]. Although sensitivity and specificity were suboptimal (69.0 and 70.4%, respectively)—likely due to the small sample size—this result is in line with those previously reported in the literature.

Conclusion: Lp(a) is independently associated with severity of CA in the subgroup of MetS patients.

Keywords: lipoprotein (a), atherosclerosis, metabolic syndrome, cardiovascular disease, ASCVD

INTRODUCTION

When metabolic syndrome (MetS) is diagnosed (Grundy et al., 2005), patients need to be accurately evaluated because of the higher risk of developing atherosclerotic cardiovascular disease (ASCVD). Carotid intima-media thickness (C-IMT) and plaques are the surrogate marker of atherosclerosis and powerful predictor of vascular outcomes in MetS patients (Pollex et al., 2006; Rundek et al., 2007; Olmastroni et al., 2019). However, the accuracy in the stratification of the carotid atherosclerosis...
METHODS

Patients
This pilot study is a sub-analysis of the previously published prospective study (Carbone et al., 2019) conducted in the outpatient clinic for the treatment of dyslipidemias and hypertension in the San Martino Hospital of Genoa, in accordance with the Declaration of Helsinki (October 2013) and approved by the Regional Ethics Committee. Informed written consent was collected from all patients at enrollment. The original cohort enrolled patients (>18 years old) with metabolic syndrome (MetS) diagnosed according to the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) criteria (Grundy et al., 2005). Exclusion criteria included acute coronary syndrome (unstable angina and myocardial infarction), congestive heart failure (NYHA class III-IV), abnormal liver or kidney function, acute and chronic infections (including HIV, HCV, and HBV), connective tissue diseases, solid or hematological tumors, endocrinopathies (including insulin or hormonal therapy (including insulin) or with recombinant cytokines. From the original cohort, we selected patients who performed ultrasound investigation of carotid atherosclerosis and for which serum sample Lp(a) assay was available. Sixty-five patients were finally included in this cross-sectional sub-analysis.

Enrolled patients underwent complete medical examination during which anamnestic data, anthropometric values [weight, height, body mass index (BMI), and waist circumference], and vital parameters (heart rate and arterial pressure on three repeated measurements) were collected.

Venous blood was collected for the evaluation of a complete lipid profile: Total cholesterol (TC), triglycerides (TAG), and high-density lipoprotein cholesterol (HDL) levels were measured enzymatically using commercial kits by Roche. LDL cholesterol was calculated by Friedewald’s formula. Lp (a) levels were determined by a nephelometry assay (Image Immune System, Beckman Coulter, Italy) with a polyclonal antibody directed against the apoprotein (a)-domain of Lp (a) in an assay insensitive to apoprotein (a) isoforms. The limit of detection was 15.62 pg/ml (Rigamonti et al., 2018).

Lp(a) was determined from the serum with nephelometric technology by means of a BN II analyzer (Gencer et al., 2019). The colorimetric enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) has been used for measuring the serum C-reactive protein (CRP) levels (Carbone et al., 2019). Carotid intima-media thickness (C-IMT) at the level of the posterior wall of the distal 10 mm of the common carotid artery (CCA) and atherosclerotic lesions were assessed by echo-color Doppler technique with a 7.5-MHz linear probe and the MyLab™ Five system (Esaote Group, Genoa, Italy). The evaluation was performed by the same operator in order to minimize the variability of the measurement.

TABLE 1 | Characteristics of sixty-five patients with metabolic syndrome.

| Variable          | Value                |
|-------------------|----------------------|
| Age, years [IQR]  | 58 (61–61)           |
| Sex, male (%)     | 40 (61.5)            |
| Waist circumference, cm [IQR] | 105 (100–112) |
| Weight, kg [IQR]  | 86 (74–97)           |
| BMI, kg/m² [IQR]  | 29.4 (27.7–32.6)     |
| SBP, mmHg [IQR]   | 143 (132–152)        |
| DBP, mmHg [IQR]   | 85 (80–92)           |
| Active smoker (%) | 19 (29.2%)           |
| T-c, mg/dl [IQR]  | 241 (204–267)        |
| HDL-C, mg/dl [IQR] | 37 (33–46)           |
| Non-HDL-C, mg/dl [IQR] | 191 (162–222)    |
| TG, mg/dl [IQR]   | 231 (157–340)        |
| Glycemia, mg/dl [IQR] | 104 (94–114)        |
| HbA1c mmol/mol [IQR] | 41 (36–44)         |
| c-IMT, mm [IQR]   | 1.00 (0.9–1.10)      |
| Lp(a), mg/dl [IQR] | 10.0 (4.0–24.0)     |
| CRP, mg/L [IQR]   | 2.8 (1.7–7.0)        |
| Ultrasound carotid plaque, n (%) | 39 (60.0%) |
| 10-year ASCVD risk (SCORE), % [IQR] | 1.8 (0.9–4.2) |

M, male; BMI: body mass index; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; T-c, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; TAG, triglyceride; HbA1c, glycated hemoglobin; c-IMT, carotid intima-media thickness; Lp(a), lipoprotein (a); CRP, C-reactive protein; ASCVD, atherosclerotic cardiovascular disease; MetS, metabolic syndrome.
**TABLE 2** Characteristics of 65 patients with metabolic syndrome divided according to the severity of carotid atherosclerosis identified with the echo-color Doppler study.

| Carotid atherosclerosis         | Moderate 0.1–1.5 mm (n = 25) | Severe >1.6 mm and/or plaque (n = 40) | p-value |
|---------------------------------|-------------------------------|--------------------------------------|---------|
| Age, years [IQR]               | 56 (49–59)                   | 59 (54–62)                           | 0.216   |
| Sex, male (%)                  | 14 (56.0)                    | 26 (85.0)                             | 0.486   |
| Waist circumference, cm [IQR]  | 104 (96–111)                 | 107 (102–113)                        | 0.641   |
| Weight, kg [IQR]               | 82 (72–88)                   | 86 (79–96)                           | 0.518   |
| BMI, kg/m² [IQR]               | 30.3 (28.3–33.7)             | 29.1 (27.6–32.2)                     | 0.434   |
| SBP, mmHg [IQR]                | 145 (140–150)                | 143 (131–151)                        | 0.491   |
| DBP, mmHg [IQR]                | 88 (80–94)                   | 85 (80–90)                           | 0.457   |
| Active smoker, (%)             | 7 (28.0)                     | 12 (30.0)                             | 0.863   |
| TC, mg/dL [IQR]                | 236 (205–257)                | 249 (203–276)                        | 0.434   |
| HDL-C, mg/dL [IQR]             | 40 (34–48)                   | 37 (32–45)                           | 0.295   |
| Non-HDL-c, mg/dL [IQR]         | 171 (153–203)                | 196 (169–225)                        | 0.064   |
| LDL-C, mg/dL [IQR]             | 153 (125–177)                | 153 (109–175)                        | 0.989   |
| TG, mg/dL [IQR]                | 201 (166–264)                | 264 (149–363)                        | 0.184   |
| Glycemia, mg/dL [IQR]          | 101 (85–109)                 | 106 (84–116)                         | 0.232   |
| HbA1c mmol/mol [IQR]           | 38 (35–43)                   | 42 (37–46)                           | 0.136   |
| Lp(a), mg/dL [IQR]             | 6 (2–12)                     | 11.5 (6–29.5)                        | **0.018** |
| CRP, mg/L [IQR]                | 2.87 (1.66–7.37)             | 2.57 (1.6–6.97)                      | 0.976   |
| 10-year ASCVD risk (SCORE), % [IQR] | 1.77 (0.63–1.47)            | 2.32 (0.94–4.07)                     | 0.716   |
| MetS criteria                  |                              |                                      |         |
| n = 3 (%)                     | 12 (48.0%)                   | 15 (37.5%)                           |         |
| n = 4 (%)                     | 7 (28.0%)                    | 16 (40.0%)                           |         |
| n = 5 (%)                     | 6 (24.0%)                    | 9 (22.5%)                            |         |
| Statin use, n (%)             | 6 (24.0%)<**/>-               | 8 (20.0%)                            | 0.762   |
| Ezetimibe use, n (%)           | 2 (8.0%)                     | 2 (8.0%)                             | 0.685   |
| Aspirin use, n (%)             | 1 (4.0%)                     | 1 (4.0%)                             | 0.975   |
| ACE-inhibitor use, n (%)       | 4 (16.0%)                    | 6 (15.0%)                            | 1.000   |
| ARB-inhibitor use, n (%)       | 9 (36.0%)                    | 24 (60.0%)                           | 0.798   |

p-value refers to comparisons between moderate and severe groups analyzed with the Mann–Whitney test. M, male; BMI, body mass index; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; G, glycemia; HbA1c, glycated hemoglobin; Lp(a), lipoprotein (a); CRP, C-reactive protein; ASCVD, atherosclerotic cardiovascular disease; MetS, metabolic syndrome; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers.

Bold underlines significant values.

inter- and intra-individual variability. CA was categorized in “moderate” (C-IMT 1.0–1.5 mm, no plaques) or “severe” (C-IMT>1.6 mm or plaques), following the international guidelines (Williams et al., 2018).

**Statistical Analysis**

Statistical analysis was performed using IBM-SPSS Statistics, Release Version 25.0 (SPSS, Inc., 2017, Chicago, IL). Kolmogorov–Smirnov analysis was performed to test the normality of variables. Therefore, biomarker data were log-transformed, where necessary. Results of continuous variables were expressed as median and interquartile range (IQR). For ordinal and nominal variables, contingency tables were used, indicating frequency and percentage (%). Mann–Whitney test was then drawn for intergroup comparison of continuous variables. The primary outcome of the study was to test the independent association of Lp(a) with severity of CA. The post hoc study power estimated for such an outcome was 0.568 (p = 0.034). The present study should be then considered as a pilot.

To identify independent variables associated with severity of CA, we then performed logistic regression analysis. Variables were log-transformed, where necessary. Finally, the receiver operating characteristic (ROC) curve has been used to verify sensitivity and specificity of the selected cut-off point of Lp(a) (MedCalc 12.5, MedCalc Software, Ostend, Belgium). All hypothesis tests were two-sided, and the significance level was set at 5%.

**RESULTS**

Demographic, clinical, and anthropometric data on sixty-five patients with evidence of asymptomatic CA are summarized in Table 1. All patients were Caucasian and without history of familial hypercholesterolemia, the median age was 58 years old, 61.5% of patients were male, and 29.2% were current smokers. As expected, BMI and waist circumference were high (median values were 29.4 kg/m² and 105 cm, respectively), reflecting the typical accumulation of visceral adipose tissue in these kind of patients. It is worth noting that despite MetS criteria being well represented in the cohort, the median 10-year ASCVD risk was 1.8, which was considered moderate. Accordingly, only one patient had a clinical history of ASCV disease. Lp(a) values range from 1 to 192 mg/dl (Supplementary Figure S1).

Among those different CV risk factors, Lp(a) emerged as the only variable differing across the study groups (moderate vs. severe CA), as reported in Table 2. Indeed, despite a prevalence of males (65% vs. 56%) and smokers (7% vs. 12%) and, generally, a worse metabolic profile, only the levels of Lp(a) were significantly different [6 (2 to 12)] mg/dl vs. 11.5 (6 to 29.5)] mg/dl; p = 0.018. We also observed no differences in the pharmacological history of
patients. In this regard, no patient was in active treatment with nicotinic acid and/or PCSK9 inhibitors.

In line with those observations, logistic regression analysis confirmed serum levels of Lp(a) as the only variable independently associated with severity of CA (Figure 1 and Supplementary Table S1). The OR for Lp(a) was indeed 2.9 with a 95% CI of 1.1–7.8. When the ROC curve was performed, a cut-off of 10 mg/dl was the best Lp(a) value, identifying patients with more severe atherosclerosis with an AUC of 0.675 (95% CI 0.548–0.786), a sensitivity of 69.0%, and a specificity of 70.4% (Figure 2).

DISCUSSION AND CONCLUSION

The major finding of the present study was the independent association between Lp(a) levels and the severity of asymptomatic CA in a selected group of patients with an established diagnosis of MetS. As widely known, MetS represents a cluster of metabolic disturbances mainly derived from the accumulation of visceral adipose tissue, and it is mild but with chronic inflammation (Gustafson et al., 2007). This condition is strictly related to the higher risk of atherosclerosis, and several studies have documented the higher prevalence of CA in MetS patients (Grundy et al., 2005; Pollex et al., 2006). Lp(a) is increasingly described as an emerging contributor to the development of atherosclerotic plaque. Several pieces of experimental evidence have indeed demonstrated the pathogenetic role of Lp(a) in atherosclerosis due to its prothrombotic/anti-fibrinolytic effect and/or its ability to cross the endothelial barrier and accumulate in the arterial wall (Gustafson et al., 2007). Therefore, it seems that the longer the lifetime exposure to high Lp(a) plasma concentrations, the higher is the risk of ASCVD (Clarke et al., 2009; Kamstrup et al., 2009). Our results are somehow confirmative of this hypothesis even though the overall values are lower than values elsewhere reported.

In the present study, Lp(a) was shown to be the only independent variable discriminating two subgroups of patients categorized according to the severity of atherosclerotic lesions. Moreover, we were able to identify a relatively low cut-off value (10 mg/d), which could help at identifying subjects with higher C-IMTs or atherosclerotic plaques. We may also speculate about a future role of
Lp(a)—even at low circulating levels—as a useful biomarker for implementing CV risk stratification. This could be applied in both primary and secondary CV prevention, combined with other recognized risk factors (as occurring in MetS).

We should acknowledge that the present study has many limitations. First, the small sample size does not allow in drawing any conclusion about clinical relevance of Lp(a) in CV risk stratification and the proportion of outlier. However, the cut-off point identified meets which were observed in the previous larger studies (Emerging Risk Factors et al., 2009; Rigamonti et al., 2018), and this may be considered a major strength of the present study.

Second, the use of nephelometric assay for the dosage of Lp(a) did not allow in evaluating the different apoprotein(a) [apo(a)] isoforms. It is indeed well-established that the lower the molecular weight of apo(a), the higher the Lp(a) concentration and the risk of atherosclerotic disease (Kraft et al., 1996). Conversely, there is a lack of clinical evidence on how aggressive lipoprotein(a) lowering reduction improves the following ASCVD risk reduction. Attention should be then maintained on the other modifiable CV risk factors (Ruscica et al., 2021; Melita et al., 2022). Furthermore, we should acknowledge a considerable amount of outlier—especially toward higher values—that should affect statistical analysis. We then have to reaffirm that the findings have to be considered preliminary.

In conclusions, this study reported that even relatively low circulating Lp(a) may be useful in discriminating patients with more severe CA. Many ongoing clinical trials are called to confirm our preliminary observation, and they eventually identify whether Lp(a) might have a clinical use in CV risk stratification (NCT03887520, NCT04023552, and NCT04310917). They are also expected to identify Lp(a) as a potential biomarker useful to address therapeutic strategies toward a more aggressive approach.

REFERENCES

Carbone, F., Elia, E., Casula, M., Bonaventura, A., Liberale, L., Bertolotto, M., et al. (2019). Baseline Ha-CRP Predicts Hypertension Remission in Metabolic Syndrome. *Eur. J. Clin. Invest.* 49, e13128. doi:10.1111/eci.13128

Clarke, R., Peden, J. F., Hopewell, J. C., Kyriaou, T., Goel, A., Heath, S. C., et al. (2009). Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. *N. Engl. J. Med.* 361, 2518–2528. doi:10.1056/nejmoa0902604

Cuspidi, C., Sala, C., Provenzano, F., Tadic, M., Gherbesi, E., Grassi, G., et al. (2018). Metabolic Syndrome and Subclinical Carotid Damage. *J. Hypertens.* 36, 23–30. doi:10.1097/jhi.0000000000001575

Emerging Risk Factors, De Faire, S., Kaprio, T., Peery, P. L., Di Angelantonio, E., Thompson, A., et al. (2009). Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. *JAMA* 302, 412–423. doi:10.1001/jama.2009.1063

Ezhov, M. V., Safarova, M. S., Afanasieva, O. I., Kukharchuk, V. V., and Pokrovsky, S. N. (2014). Lipoprotein(a) Level and Apolipoprotein(a) Phenotype as Predictors of Long-Term Cardiovascular Outcomes after Coronary Artery Bypass Grafting. *Atherosclerosis* 235, 477–482. doi:10.1016/j.atherosclerosis.2014.05.944

Gencer, B., Rigamonti, F., Nanchen, D., Vuilleumier, N., Kern, I., Aghilmandi, S., et al. (2019). Prognostic Value of Elevated Lipoprotein(a) in Patients with Acute Coronary Syndromes. *Eur. J. Clin. Invest.* 49, e13117. doi:10.1111/eci.13117

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., et al. (2005). Diagnosis and Management of the Metabolic Syndrome. *Circulation* 112, 2735–2752. doi:10.1161/circcdaha.105.169404

Gustafson, B., Hammarstedt, A., Andersson, C. X., and Smith, U. (2007). Inflamed Adipose Tissue. *Arthritis*. 27, 2276–2283. doi:10.1016/j.atvbaha.170.147835

Kamstrup, P. R., Tybaer-Hansen, A., Steffensen, R., and Nordestgaard, B. G. (2009). Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. *JAMA* 301, 2331–2339. doi:10.1001/jama.2009.801

Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., and Laufs, U. (2020). Targeting RNA with Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias. *J. Am. Coll. Cardiol.* 76, 563–579. doi:10.1016/j.jacc.2020.05.070

Kraft, H. G., Lingenhel, A., Köchli, S., Hoppichler, F., Kronenberg, F., Abe, A., et al. (1996). Apolipoprotein(a) Kringle IV Repeat Number Predicts Risk for Coronary Heart Disease. *Arthritis*. 16, 713–719. doi:10.1161/01.atv.16.6.713

Lp(a)Horizon (2022). Lp(a)HORIZON [Online]. Available: https://www.lpahorizon.com

Olmastroni, E., Baragetti, A., Casula, M., Grigore, L., Pellegatta, F., Pirillo, A., et al. (2019). Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. *Stroke* 50, 1758–1765. doi:10.1161/strokea.118.024692

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Regional Ethical Committee. The participants and their informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ALC, AP, FC, NA, SB, AP, FM, and LP enrolled the cohort; ALC, AP, FC, LV, MC, EE, AB, LL, MB, NA, SM, PC, DV, FM, and LP assessed biochemical parameters and run the experiments; ALC, AP, FC, LV, and LP analyzed the data; ALC, AP, and FC drafted the manuscript. All authors were actively involved in the design of the study or provided critical comments for its development. All authors revised the manuscript and approved its submission.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.854624/full#supplementary-material

Supplementary Figure S1 | Box plot illustrating Lp(a) distribution across the study groups. Black circles represent the outlier values as identified by the iterative Grubb’s test.

Supplementary Table S1 | Regression analysis for TSA severity in patients with evidence of carotid atherosclerosis.
Orsó, E., and Schmitz, G. (2017). Lipoprotein(a) and its Role in Inflammation, Atherosclerosis and Malignancies. Clin. Res. Cardiol. Suppl. 12, 31–37. doi:10.1007/s11789-017-0084-1

Pollé, R. L., Al-Shali, K. Z., House, A. A., Spence, J. D., Fenster, A., Mamakeesick, M., et al. (2006). Relationship of the Metabolic Syndrome to Carotid Ultrasound Traits. Cardiovasc Ultrasound 4, 28. doi:10.1186/1476-7120-4-28

Rigamonti, F., Carbone, F., Montecucco, F., Bonaventura, A., Liberale, L., Burger, F., et al. (2018). Serum Lipoprotein (A) Predicts Acute Coronary Syndromes in Patients with Severe Carotid Stenosis. Eur. J. Clin. Invest. 48. doi:10.1111/eci.12888

Rundek, T., White, H., Boden-Albala, B., Jin, Z., Elkind, M. S. V., and Sacco, R. L. (2007). The Metabolic Syndrome and Subclinical Carotid Atherosclerosis: the Northern Manhattan Study. J. Cardiometab Syndr. 2, 24–29. doi:10.1111/j.1559-4564.2007.06358.x

Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., and Sahebkar, A. (2021). Lipoprotein(a): Knowns, Unknowns and Uncertainties. Pharmacol. Res. 173, 105812. doi:10.1016/j.phrs.2021.105812

Tsimikas, S. (2017). A Test in Context: Lipoprotein(a). J. Am. Coll. Cardiol. 69, 692–711. doi:10.1016/j.jacc.2016.11.042

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. (2018). 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. J. Hypertens. 36, 1953–2041. doi:10.1097/hjh.0000000000001940

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cremonini, Pasta, Carbone, Visconti, Cassola, Elia, Bonaventura, Liberale, Bertolotto, Artom, Minetti, Contini, Verzola, Pontremoli, Viazzi, Viviani, Bertolini, Pende, Montecucco and Pisciotta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.